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The human body consists of about 10 times as many bacteria as our own body cells. 
Only the gastrointestinal tract can hold up to 400 different bacterial species, where 
the majority of the bacteria are concentrated to the large intestines. We are born sterile 
without any microbiota, but thereafter colonizing and development of the microbiota 
occur over time. Probiotics are good bacteria that are supplied via food or as dietary 
supplements. The most common of probiotic bacteria belongs to the genera Lactoba-
cillus or Bifidobacterium. They are classified as safe bacteria which makes them very 
popular to use in probiotic products. Both genera are Gram positive, rod-shaped and 
can ferment carbohydrates to short-chain fatty acids that lower the pH and make it 
unfavorable for other bacteria. Some guidelines for probiotics are that it must contain 
live bacteria and be resistant to gastric acid and bile salts. 
 
In this literature study focus has been on how probiotics affect the gastrointestinal 
tract which in turn can affect the health. To narrow down the work four different 
probiotic strains that are common on the Swedish market have been selected for fur-
ther studies: Lactobacillus reuteri Protectis DSM 17938, Lactobacillus rhamnosus 
GG (LGG), Lactobacillus plantarum 299v and Bifidobacterium animalis BB-12. 
 
The general mechanism of action for probiotic bacteria is that they temporarily can 
persist in the intestine and be able to produce antimicrobial substances that can inhibit 
pathogenic bacteria. Probiotic bacteria should also be able to compete with other bac-
teria about nutrition and bind to epithelial cells to strengthen the immune system. 
 
Studies have shown that Lactobacillus rhamnosus GG reduces the risk of suffering 
from antibiotic-associated diarrhea both in children and adults and that Lactobacillus 
reuteri DSM 17938 reduces the time of crying with 30-70 minutes per day in infants 
with colic. 
 
Analyzing the effect of probiotics is a challenge as the effect can vary widely from 
individual to individual. Also, most studies vary greatly in performance, duration and 
dose given to patients. There are also more studies on mono strained probiotics than 
on multi strained. Due to the fact that multi strained probiotics makes it more difficult 
to evaluate which strain has had the best effect the studies are harder to compare. 
 
Since probiotics are classified as safe and harmless bacteria it can always be a good 
start to treat gut dysbiosis with probiotics. 
 
Keywords: intestinal microbiota, probiotics, probiotic mechanism of action, gut mi-
crobiota, irritable bowel syndrome, IBS, microbial ecology 
Abstract 
 
 
En människokropp består av ungefär 10 gånger så många bakterier som egna kropps-
celler. Bara mag- och tarmkanalen rymmer upp till 400 olika bakteriearter, där bak-
terierna är mest koncentrerade i tjocktarmen. Vi föds sterila utan någon mikrobiota 
varefter vi snabbt koloniseras och mikrobiotan utvecklas med tiden. Probiotika är 
goda bakterier som tillförs via livsmedel eller som kosttillskott. De vanligaste släk-
tena av probiotiska bakterier är Lactobacillus och Bifidobacterium. De är klassade 
som säkra bakterier vilket gör att de är väldigt populära att använda i probiotiska 
produkter. Båda släktena är Gram-positiva, stavformade och kan fermentera kolhyd-
rater till kortkedjiga fettsyror som sänker pH och gör det ogynnsamt för andra bakte-
rier. Några riktlinjer för probiotiska produkter är att de måste innehålla levande bak-
terier som är resistenta mot magsaft och gallsalt. 
 
I denna litteraturstudie har fokus legat på hur probiotika påverkar mag- och tarmka-
nalen som i sin tur kan påverka hälsan. För att smalna av arbetet har fyra olika pro-
biotiska stammar, som är vanligt återkommande på den svenska marknaden, valts ut 
för att studeras mer ingående: Lactobacillus reuteri Protectis DSM 17938, Lacto-
bacillus rhamnosus GG (LGG), Lactobacillus plantarum 299v och Bifidobacterium 
animalis BB-12. 
 
Den generella verkningsmekanismen för probiotiska bakterier är att de under en tid 
stannar i tarmen och då producerra antimikrobiella substanser som kan inhibera pa-
togena bakterier. Probiotiska bakterier ska även kunna konkurrera med andra bakte-
rier om näring och om att binda till epitelceller för att stärka immunförsvaret. 
 
Studier har visat att Lactobacillus rhamnosus GG minskar risken för att drabbas av 
antibiotikaassocierad diarré både hos barn och vuxna, och att Lactobacillus reuteri 
DSM 17938 sänker gråttiden hos spädbarn med kolik med 30-70 minuter per dag. 
 
Att analysera effekten av probiotika är en utmaning då effekten kan skifta mycket 
från individ till individ, samtidigt som de flesta studier varierar i utförande, varaktig-
het och dos som patienterna får. Det finns också fler studier på probiotika med en 
stam än på produkter med flera. På grund av att en produkt med flera stammar gör 
det svårare för att utvärdera vilken av stammarna som har gett bäst effekt blir studi-
erna svårare att jämföra. 
 
Eftersom probiotika klassificeras som säkra och ofarliga bakterier kan det alltid 
vara en bra början att behandla tarmdysbios med probiotika. 
 
Nyckelord: intestinal microbiota, probiotics, probiotic mechanism of action, gut mi-
crobiota, irritable bowel syndrome, IBS, microbial ecology  
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1.1 What is probiotics? 
Probiotics is a hot topic today with many commercials on television marketing new 
products that can provide a well-functioning intestine, which in turn, can lead to an 
overall healthier lifestyle and wellbeing. The human body consists of almost ten 
times more bacteria than the body’s own cells and most of the bacteria are concen-
trated to the intestines and more specifically the colon (Gerritsen et al., 2011). It has 
been established that the gastrointestinal (GI) tract holds about 400 different species 
of bacteria (Gerritsen et al., 2011). During birth the newly born comes from a sterile 
environment and immediately a bacterial colonization starts to build up (Araya et 
al., 2006). Some bacteria are harmful while others favour us. These friendly bacteria 
that are presented in the colon and promotes a functional eco-system and maintains 
the homeostasis within the body are called microbiota. Unlike the existing microbi-
ota that are established in the gut, favorable bacteria that comes from food or sup-
plements which contain friendly bacteria, are called probiotics (Roos, 2018). 
 
Probiotics are believed to be newly discovered but there is evidence going all the 
way back to the Old Testament that people consumed fermented milk (Fuller, 1992). 
Through the years fermented milk has been a way of preventing food spoilage and 
in the beginning of the 20th century Elie Metchnikoff, professor at the Pasteur In-
stitute in Paris, determined that the microflora of the gut influenced the wellbeing 
of humans and that people who drank fermented milk lived longer. Going back in 
the history when the diet consisted of natural food from a natural environment there 
were no need of probiotics. But over time both the lifestyle and the environment 
have changed, and several causes can contribute to a dysbiosis in the gut. Some 
effects can be connected to inferior diet with artificial and processed food, antibiot-
ics that expels the favourable bacteria or a more excessive cleanliness. Nowadays 
1 Introduction 
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probiotics instead has become a supplement for repairing deficiencies in the human 
body (Fuller, 1992) 
 
There are a lot of species and strains that can be used as probiotics, and the far most 
used in Sweden are strains of Lactobacillus (Fuller, 1992) and Bifidobacterium but 
certain strains of Lactococcus, Streptococcus, Pediococcus and Leuconostoc can 
also be used. Strains of Lactobacillus and Bifidobacterium are stated as safe and are 
the far most used ones. They are Generally Recognized As Safe (GRAS) which 
means that there is no doubt that they are not harmful. According to the FAO/ WHO 
probiotics are “Live microorganisms which when administered in adequate amounts 
confer a health benefit on the host”. There are some guidelines for probiotics (Araya 
et al., 2006): 
 
➢ the product must contain living microorganisms 
➢ there must be an adequate dose of probiotics pointed out on the product for 
achieving an effect 
➢ the probiotic bacteria must survive not only in the passage through the gas-
trointestinal but also survive and proliferate in the gut which means the bac-
teria needs to be resistant towards gastric juices and bile. 
 
Probiotic bacteria can ferment carbohydrates that contribute to a low pH in foods. 
They are mostly found in fermented foods, but nowadays it can be found in juices 
and other drinks, if added. The fermented foods can be everything from yoghurt and 
cheese to sauerkraut and kimchi. In the gut the bacteria of the microbiota and some 
probiotic bacteria can digest dietary fibers that cannot be digested in the small in-
testines. Fibers that contribute to a more beneficial microbiota are called prebiotics. 
The probiotic bacteria can also compete and inhibit the action of other pathogenic 
bacteria by competing for nutrients or compete for binding to the mucosal surface 
of the intestines. They can also stimulate enzymatic reactions and synthesize vita-
mins (Fuller, 1992). 
 
1.2 Products containing common probiotic strains in 
Swedish food- and drugstores 
Most Swedish supermarkets have a large stock of products that contain probiotics. 
Also, Swedish drug stores offers a lot of different supplements that can contribute 
to a healthier microflora. The recommended dose of intake per day for probiotics is 
109-1010 colony forming units (CFU) to get a positive effect of the health 
(Hemaiswarya et al., 2013), but even lower doses can show positive effects. 
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Lactobacillus is the most popular used probiotic and there are a lot of strains that 
are used in different products. Lactobacillus can ferment carbohydrates to lactic 
acid, acetic acid and ethanol while Bifidobacterium can ferment carbohydrates and 
the end products are acetic acid and lactic acid (O'Callaghan & van Sinderen, 2016). 
Both Lactobacillus and Bifidobacterium are Gram positive bacteria. Lactobacillus 
are oxygen tolerant, rod-shaped and non-spore-forming bacteria. They are mostly 
found naturally in animal feed, ensilage and milk products and are added to food 
products like sour cream, cheese and fermented vegetables to give it the character-
izing taste and a longer sustainability. Bifidobacterium naturally occurs in the intes-
tines of mammals, as well as the oral cavity of humans and in sewages (O'Callaghan 
& van Sinderen, 2016). They are rod-shaped and sensitive to oxygen. 
 
Many companies have patent on different strains and have even given them names 
that only that company uses. The Trademark for a probiotic strain extends over 20 
years, and then that strain is allowed to be used by other companies if renamed 
(Roos, 2018). There are many products on the market and four species that are re-
peatedly used on the Swedish markets are: 
1.2.1 Lactobacillus reuteri 
L. reuteri was discovered by the German microbiologist Gerhard Reuter (Britton, 
2017). A lot of different strains of L. reuteri are found and in Sweden and the strain 
Lactobacillus reuteri Protectis DSM 17938 is strongly associated with the company 
BioGaia that has patent on the strain and that makes supplements in shapes of tab-
lets, liquids or powder form. L. reuteri can be one of the first bacteria that the newly 
born baby meets through the birth and breastfeeding. The bacteria can naturally live 
in humans but often in relatively low numbers. L. reuteri can produce a metabolic 
compound, reuterin, that can inhibit pathogenic bacteria (Karimi, 2017). 
1.2.2 Lactobacillus rhamnosus 
Lactobacillus rhamnosus GG (LGG) was discovered 1985 by Sherwood Gorbach 
and Barry Goldin (Segers & Lebeer, 2014). On the Swedish market the L. rhamno-
sus can be found in Bifiform from the drug stores where it is sold as lactic acid pills. 
The strain can produce antimicrobial compounds, bacteriocins, that can inhibit an-
aerobic bacteria such as Clostridium, Staphylococcus etc (Gorbach et al., 2017). The 
bacteria can lower the pH in the intestines and inhibit pathogenic organisms 
(Hemaiswarya et al., 2013). 
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1.2.3 Lactobacillus plantarum 
L. plantarum can ferment a lot of different carbohydrates and have a high tolerance 
towards bile and acids (Molin, 2015). L. plantarum increases the amount of acetic 
acid and propionic acid that makes the environment unfavourable for pathogenic 
bacteria (Ducrotte et al., 2012). Probi mage is a product in Swedish drug stores that 
contains Lactobacillus plantarum 299v as a single strain (Probi Mage 80 kapslar, 
2018). Also the trademark Proviva that provides fruit drinks in supermarkets contain 
Lactobacillus plantarum 299v as a single strand (ProViva, 2013). 
1.2.4 Bifidobacterium animalis spp. lactis 
B. animalis spp. lactis can be found in the colon of mammals and is resistant to 
oxidative stress and acidity (Quigley, 2017). The company Chr. Hansen A/S have 
had a patent on the strain Bifidobacterium animalis DSM 15954 which they named 
BB-12. The strain can be found in products of Bifiform and in certain types of yo-
gurts sold in the supermarkets. 
 
1.3 Isolation of bacteria 
Lactobacillus reuteri was first isolated 1990 from a peruvian woman’s breastmilk 
(BioGaia). The bacteria are common in the microbiota of humans and is isolated 
from breastmilk, vagina, oral cavity, stomach, small intestine, colon and feces. It 
can survive acids and bile salts that naturally occurs in the intestinal tract. 
 
Lactobacillus rhamnosus was first isolated from healthy human feces by Sherwood 
Gorbach and Barry Goldin in 1985 (Gorbach et al., 2017). Due to its characteristics 
as resistance to bile and acid, good growth and adhesion capacity to the epithelial 
cells it is preferable as probiotics (Segers & Lebeer, 2014). 
 
Lactobacillus plantarum have been isolated from healthy human intestinal flora 
(Molin, 2015). The bacteria was isolated and studied in a science project in Lund 
1986 to come up with a nutrition supplement for patients with tube feeding 
(ProViva, 2013). 
 
Bifidobacterium animalis spp. lactis was discovered by the French paediatrician 
Henry Tissier that determined that there were a higher number of Bifidobacterium 
in healthy children compared to children with diarrhea (Araya et al., 2006). The first 
isolation was taken from milk cultures, which makes milk products a very good 
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environment for the probiotic bacteria to grow in (Quigley, 2017). B. animalis spp. 
lactis can be divided into two subspecies; B. animalis and B. lactis. B. animalis is 
resistant to oxidative stress and acidity. 
1.4 Probiotic bacterial mechanism of action 
 
There are a lot of mechanisms that the probiotic bacteria can work through, and it 
differs a lot from one species or strain to another. Favorable for probiotic bacteria 
is to colonize the gut, produce antimicrobial substances, compete with other bacte-
ria for binding to epithelial cells, compete for nutrients and modulate the immune 
system (Araya et al., 2006). One general problem that can cause a lot of disorders 
and diseases in the human intestines often starts with a leaky gut (Roos, 2018). In 
the same way as nutrients can pass the epithelial cells from the intestines to the 
blood, the bacteria can pass it the same way and cause diseases. 
 
The gastrointestinal tract is complex and starts with a layer of mucus that provides 
the intestines with a protective barrier (Karimi, 2017). The mucus layer is the first 
immune barrier the bacteria faces. The attachment to the mucus often comprises 
binding protein that the probiotic bacteria secretes. Furthermore, the probiotics can 
produce antimicrobial compounds like bacteriocins, hydrogen peroxide, nitric ox-
ide, lactic acid, acetic acid and butyric acid that impairs the environment for other 
bacteria (Hemaiswarya et al., 2013). 
 
If a pathogen penetrates the mucus it faces the epithelial cells that are the major 
defense of the immune system in the gut (Karimi, 2017). These epithelial cells are 
bound together with junctions. The tight junction which is the first barrier of the 
epithelial junctions control the regulation of micro- and macro molecules between 
the epithelial cells. The two other junctions are adhesion junction and desmosome. 
They regulate the communication and adhesion between the cells. There is evidence 
that pathogens can enfeeble the tight junctions between the epithelial cells while 
probiotics can amplify the mucosal layer, repair the junctions and the binding pro-
teins by extrude metabolites that activate genes. 
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The aim of this study was to get an understanding how probiotics works and to 
compare the most used probiotic strains in Sweden to each other to get a bigger 
knowledge in what effect they have in the body. To narrow down the area the great-
est importance has been to study the probiotic effect on mostly healthy people or 
people suffering from minor gut diseases or disorders like irritable bowel syndrome 
(IBS), antibiotic-associated diarrhea (AAD) and abdominal pain.  
 
The questions requested was: 
 
➢ Which probiotic bacteria are the most common used in Sweden and where 
have they been isolated from? 
 
➢ What have earlier studies shown? What positive and non-positive effects 
have the probiotic bacteria shown? 
 
➢ What characteristics do the bacteria have in the intestines? 
 
➢ Are there any differences between the mechanism of action according to the 
probiotic bacteria? 
 
2 Purpose and question at issue 
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To get a background about what probiotic bacteria are, where they come from and 
what they do the book Probiotics - the scientific basis written by R. Fuller was used. 
Even some articles about microflora, gastrointestinal tracts and probiotics were read 
to get a greater knowledge about the human body and how the bacterial flora of the 
gut affects the human health. For further studies a literature survey was performed 
were most of the articles were found by searching in the database Web of Science. 
Both clinical studies and META-analysis were studied. Clinical studies were used 
to see what certain studies have shown and the META-analysis were read and eval-
uated to compare a large stock of clinical trials to get a trustworthy outcome and a 
more accurate result. The relevance of the articles was assessed by their models so 
that the clinical studies compared were randomized, double-blinded and placebo-
controlled. Great importance was given to the year of publicity and most of the ma-
terial was published between 2013 and 2017. 
3 Method 
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4.1 Efficiency of probiotics 
The efficiency of probiotics can vary. Four different META-analysis has been au-
dited and summarized below. 
 
One META-analysis compiles the probiotic effect of Lactobacillus rhamnosus GG 
compared to a placebo effect in children and adults suffering from antibiotic-asso-
ciated diarrhea (AAD) (Szajewska & Kolodziej, 2015). The analysis compared 12 
different randomized controlled clinical trials (RCTs) and 1499 patients partici-
pated. The daily intake of probiotic varied between 4*108 to 12*1010 colony forming 
units (CFU) per day. The probiotics was compared with placebo or with no addi-
tional treatment. In total this META-analysis showed that L. rhamnosus GG reduced 
the risk of getting the AAD from 22.4% to 12.3%. for all participants When the 
results were divided between adults and children the results differed significantly 
between the groups. The group of children that had an intake of probiotics reduced 
the risk of getting AAD from 23% to 9.6% while in the group of adults it was re-
duced from 22.2% to 13.7%.  The results showed that the AAD significantly was 
reduced in children but not in adults. 
 
Another META-analysis evaluated the effect of Lactobacillus reuteri DSM 17938 
and other treatments on infants suffering from colic (Gutierrez-Castrellon et al., 
2017). The META-analysis consisted of 32 randomized controlled clinical trials 
(RCTs) with 2242 patients randomized into 9 different groups that compared differ-
ent treating techniques: massage, acupuncture, drugs, herbal, dietetics, reassurance, 
different manipulations and a placebo.  
 
 
 
4 Results 
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Table 1. Shows different treatments that was given to infants with colic. 
 
Diet Hydrolyzed formulas, isolated 
soy protein formulas, prebiotic 
added infant formulas 
Lactobacillus reuteri DSM 17938  Lactobacillus reuteri DSM 
17938 (108 CFU/ day) 
Drugs Dicyclomine, cimetropium or si-
methicone 
Herbal Fennel seed oil, Menta piperita, 
Melissa officinalis, Matricariae 
recutita or Foeniculum vulgare 
Acupuncture Local or systematic acupuncture 
Manipulative Car-rides interventions, decrease 
of stimulating actions, chiroprac-
tic techniques 
Massage Spinal massage or any kind of 
massage 
Reassurance Familiar caregivers support, 
counseling therapies 
Control Placebo 
 
 
Randomized clinical trials (RCTs) used were published between 1960 and 2015. 
The results in table 2 shows that the L. reuteri was far most effective compared to 
the other methods. For 95% of the infants treated with L. reuteri the reduction of 
crying decreased with 30-70 minutes. On the second place came dietetics interven-
tions. 
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Table 2. Comparisons between different treatment for colic in infants. Weighted 
mean differences shows the reduction of crying in minutes, Cl95% shows a 95% con-
fidence interval, P value shows the probability and the I2 is an imaginary number. 
 
Intervention Weighted 
mean differ-
ences (min) 
Cl95%, min P value Heterogene-
ity I2 (%), 
P value 
L. reuteri 
DSM 17938 
-51.3 -30.5 to -72.2 0.0001 42, 0.08 
Dietic -44.3 -18.7 to -56.1 0.0001 83, 0.001 
Manipulative 37.4 -21.5 to -67.0 0.001 78, 0.001 
Massage -40.0 -2.0 to -78.0 0.04 0, 0.83 
Acupuncture -11.2 2.0 to -23.0 0.08 0, 0,40 
Herbal -61.2 0.8 to -122.0 0.05 98, 0.001 
Drugs -30.0 -20.8 to -39.0 0.001 63, 0.01 
Reassurance -52-6 56.0 to -161.4 0.34 99, 0.001 
 
 
The third META-analysis was a literature study that analyzed how probiotics affect 
different kinds of irritable bowel syndrome (IBS). The different syndromes com-
pared was IBS with predominantly diarrhea (IBS-D), constipation (IBS-C), a mix 
of diarrhea and constipation (IBS-M) or unspecified (IBS-U) (Principi et al., 2018). 
More than 800 articles were compiled, and they were published between January 
2000 and June 2017. The participants needed to come up with at least two criteria 
to participate in these studies: pain associated with defecation, difference in feces 
frequency and/ or changes in the texture of the feces. 
 
What was established was that when mucosal and/ or fecal microbiota was analyzed 
patients from the healthy control groups they had a larger diversity of the microbiota 
than patients suffering from IBS (Principi et al., 2018). It also differed from children 
and adults since children do not have a full established microbiota. What was deter-
mined of the microbiota was that the beneficial bacteria such as Lactobacillus spp. 
and Bifidobacterium spp. did not play such a big role as it was supposed. The 
amount of these bacteria was reduced, increased or unchanged while the number of 
possible detrimental bacteria like Clostridium spp. was found in a higher concentra-
tion in patients suffering from IBS. The conclusions were that probiotic was signif-
icantly effective against IBS for a big part of the participants and strains Bifidobac-
terium breve, Bifidobacterium longum and Lactobacillus acidophilus showed the 
best results when treating IBS while Bifidobacterium animalis, Bifidobacterium in-
fantis, Lactobacillus casei, Lactobacillus plantarum and Lactobacillus bulgaricus 
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had no effect. According to abdominal distension probiotics that improved were 
Bifidobacterium breve, Bifidobacterium infantis, Lactobacillus casei and Lactoba-
cillus plantarum. For flatulence all the probiotics showed improvements. The data 
showed positive effects for the use of probiotics, but it needs more research for dose 
and duration to treat different types of IBS. 
 
The fourth META-analysis compiled the effect of probiotic efficacy for a number 
of different GI diseases (Ritchie & Romanuk, 2012). 
 
Table 3. Shows the diseases that was analyzed in this META-analysis. 
 
Diseases analyzed 
Pouchitis 
Infectious diarrhea (ID) 
IBS 
Helicobacter pylori 
Clostridium difficile disease 
AAD 
Traveler’s diarrhea 
Necrotizing Enterocolitis 
 
The clinical trials used stretched between 1970 and 2011 and they were collected 
from Pubmed, Medline, Google Scholar, Embase, Biological Abstracts and Science 
Direct. The probiotics used are showed below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
21 
 
 
Table 4. Shows the probiotics used to treat different diseases in this META-analysis. 
The probiotics in bold are the two of the four most used strains in Sweden. 
 
Probiotics used 
VSL#3 
LGG 
S. boulardii 
B. infantis 
L. acidophilus 
L. casei 
C. butyricum 
E. faecum 
L. plantarum 
B. lactis 
L. acidophilus + B. in-
fantis 
 
 
In total of eight diseases only Pouchitis, AAD, ID, IBS, Helicobacter pylori and 
Clostridium difficile were improved when treated with probiotics. Pouchitis was af-
fected by all probiotic strains while Traveller’s diarrhea and Necrotizing Enterocol-
itis did not show any significant effect of the probiotics. The probiotics that showed 
most effect according to all the GI diseases were VSL#3, E. faecium, C. butyricum, 
L. acidophilus combined with B. infantis, B. lactis, LGG, L. casei and S. boulardii. 
VSL#3 and C. butyricum showed best effect of all probiotics. It was also established 
that L. acidophilus as a single strain was more effective than in a mixed strain, and 
that the age of the participants or the dose that was given did not show any signifi-
cant efficacy. On the other hand, the length of the treatment showed more efficacy 
for a longer treatment (9-240 weeks) than a shorter (3-4 weeks). 
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4.1.1 Efficacy of mechanism of action 
As earlier mentioned in the introduction there are several possible mechanisms of 
action for the probiotic bacteria. One is to upregulate or downregulate immune mol-
ecules that affect the immune system. One hypothesis of a mechanism is the im-
munomodulation by probiotics (Hemaiswarya et al., 2013). The probiotic bacteria 
bind to the mucus where it meets either the epithelial cells, the Microfold cells (M 
cells) or the Dendritic cells. The interaction stimulates both the epithelial cells to 
release Interleukin 6 (IL-6) that is a pro-inflammatory cytokine, and it stimulates 
the macrophages and Dendritic cells to produce TFN-α and IFN-γ. 
 
Probiotic bacteria can also stimulate Mast cells to produce cytokine IL-4, and to-
gether with the cytokine IL-6 that the epithelial cells secrete and TGF-β they can 
change the production of IgM to IgA (Hemaiswarya et al., 2013). It has also been 
shown that an increase of the antibodies IgM and IgG and a decrease of the inflam-
matory antibody IgE. 
 
4.1.2 Multi strained probiotics 
A multi strained probiotic supplement can either contain several strains of the same 
species or strains from different probiotic species (Timmerman et al., 2004). As the 
gut contains more than 400 different species it has been hypothesized that a multi 
strained probiotic has a bigger chance to colonize the gut and produce a greater 
variety of microbial substances like bacteriocins that can work in synergism and 
inhibit pathogenic bacteria in a more effective way than a single strained probiotic. 
In one study both single strained probiotics, multi strained probiotics and multi-
species showed positive effects on diseases but the multispecies showed best results. 
The disadvantages of multi strains or multispecies are that the probiotic bacteria can 
inhibit each other, and it can be hard to analyze the result to see which strain or 
species that promoted the best effect. 
4.1.3 Single strained probiotics 
A single strain probiotic only contain probiotic from one strain of a species 
(Timmerman et al., 2004). The advantage of a single strained probiotic is that no 
other species or strains can interrupt or inhibit the mode of action. It makes it easier 
to evaluate the effect of a single strained probiotics as there is only one strain that 
can affect the outcome. The mono strain does not either have to compete with other 
probiotic strains about the nutrients. The disadvantage of using a single strain 
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probiotic supplement is that if the probiotics does not give any effects, there will not 
be any other strains that can complete the effect. 
4.2 Survival in guts 
There are several different methods to determine the gastrointestinal microbiota in 
humans. Old molecular techniques as quantitative polymerase chain reaction 
(qPCR), temperature or denaturing gradient gel electrophoresis, terminal-restriction 
fragment length polymorphism (T-RFLP) and fluorescent in situ hybridization 
(FISH) have been used to see the diversity of bacteria in the intestines (Gerritsen et 
al., 2011). Nowadays a faster way of sequencing a human’s whole genome is to use 
Next Generation Sequencing (NGS) which only takes one single day (Behjati & 
Tarpey, 2013). Another method of determine the microbiota of a person is to study 
the feces as the colon and feces contains more bacteria per gram comparison to the 
content of bacteria in the stomach or in the small intestines. It is also a god way 
because there is no need of surgical procedures like biopsies. From the fecal samples 
the biomass of microbial cells can be determined. 
 
The probiotic bacteria must survive gastric acidity and bile salts (Bezkorovainy, 
2001). Depending on the strength and length of exposure to acidity and bile salts 
probiotic bacteria can survive differently. Many probiotics work their way through 
the intestines where they may multiply and bind to the mucus but still do not colo-
nize, therefore a continuous intake of probiotic supplement is favorable. 
4.3 Favorable food for the probiotic bacteria 
As mentioned earlier some foods are improved to favor the probiotic bacteria. Es-
pecially indigestible sources as dietary fibers and resistant starch can not be digested 
in the gut or in the small intestines. Later in the colon some of the probiotic bacteria 
can digest it and produce short chain fatty acids (SCFA). The SCFA lowers the pH 
and can inhibit proteolytic bacteria. The probiotic bacteria can even produce vita-
mins as K and B12 that the body is incapable to produce itself (Gerritsen et al., 
2011). 
 
Foods that stimulate the positive bacteria in the intestines are called prebiotics. 
Prebiotics may also stimulate the growth of probiotic bacteria, and together they are 
mentioned synbiotics. The criteria for prebiotics is that they need physical properties 
that can withstand the digestive process (Wang, 2009). They need to be resistant to 
bile salt and acids, can be fermented by certain gut bacteria in the colon and/ or to 
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stimulate the growth of probiotic bacteria (Gibson et al., 2004). The downside of 
prebiotics nowadays is that a large part of the population gets flatulence and stom-
achache because of the decrease of friendly bacteria in the gut due to their diets. 
 
Studies have been performed to see what dietary fibers that promotes the probiotic 
bacteria best. Still the studies needs improvements and more research but it showed 
that inulin showed best effect towards probiotics (Gibson et al., 2004). 
 
Inulin is the far most researched dietary fiber and it belongs to the fructans of car-
bohydrates (Clase & Nertby Aurell, 2015). Inulin can be found in a large scale in 
Jerusalem artichokes. Pectin is another dietary fiber that can be found in the peel of 
different citruses and almost 100% of the pectin makes it way to the colon without 
being broken down. Also, beta glucans are common dietary fibers and the most pop-
ular way of intake comes from porridge as the oats contains lots of beta glucans. 
4.4 Influence of external factors 
Age, health, gender, ethnicity, geographic location, genetics and diet are all factors 
that can promote or inhibit the effect of probiotics (Marco & Tachon, 2013). There 
are evidences that the diet affects how much nutrients that are available for the pro-
biotic bacteria and how well they can proliferate. Due to a modern diet a lot of peo-
ple have a reduced number of certain members of the microbiota as they have not 
been given them enough nutrients to keep them alive. 
 
For infants breast-feeding contra formula-feeding gives different intestinal microbi-
ota (Gerritsen et al., 2011). The breast-feed infants have a larger diversity of 
Bifidobacterium spp. while the formula-feed have a larger diversity of Clostridia, 
Enterobacteriaceae, Bacteroides and Enterococcus. Later during the first year when 
the baby starts to eat solid food the microbiota starts to develop into an adult acting 
microbiota. 
 
A lot of elderly people suffer from decreased intestinal motility, as well as lost ap-
petite which can lead to a decreased nutritional intake that affect the intestinal mi-
crobiota (Gerritsen et al., 2011). 
 
In a study the gut microbiota of European children from Italy was compared to the 
microbiota of children from Burkina Faso in Africa (De Filippo et al., 2010). 
Though the diet in Burkina Faso consists in high fiber, lot of starch and plant 
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saccharides and less meat it showed that their microbiota was well established com-
pared to the microbiota of European children. 
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It can be a challenge to determine how effective probiotics are. The mechanism of 
action differs from bacteria to bacteria and it is not well established in which way 
each one works. Every single bacteria affects differently for each person depending 
on the composition of the microbiota, what you eat, how old you are and if you are 
healthy or not. On the other side another factor that makes it hard to analyze the way 
probiotics works is if the intake is combined with other probiotics that may inhibit 
or favor each other. It is tricky to see which of the probiotics that works best in a 
multiple probiotic supplement. 
 
Some META-analysis determined that a bias was that studies that was supposed to 
be double-blinded ended up with the administrators revealing what supplement that 
was used, which can affect the results. Overall the bias with these kinds of studies 
is the ability to keep them double-blinded to exclude impact. 
 
The difficulties in META-analysis is that there are fewer clinical studies comparing 
the effect of several probiotics treating different diseases. The existing ones are of-
ten completed by companies that wants to come up with a new product. The studies 
are also very different in the configuration. Daily dose of probiotics, the duration of 
the study and how often follow-ups exists differs from study to study. 
 
There are much more clinical studies available on single strained probiotics than 
studies of multiple strained probiotics. That is because it is easier to evaluate the 
effect of a single stranded probiotics than a multi stranded. Overall there is not so 
many studies comparing different probiotic supplements when treating a disease 
which would have been interesting to see what strain that is most effective regarding 
to a specific disease. 
 
There are a lot of evidence that probiotics contribute to health, and from all the 
clinical reports and META-analysis studied it showed that probiotic favor the 
5 Discussion 
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function of the intestines which in turn favors the immune system and mitigate most 
of the gut dysbiosis although with different effectivity. There need to be more stud-
ies of how probiotic bacteria effect the microbiota. 
 
During the second half of the last century Western countries have develop antibiot-
ics that impede pathogenic bacteria, but at the same time allergies, gut dysbiosis 
leading to IBS and some autoimmune disorders increased. Probably they go hand in 
hand as antibiotics can disrupt the microbiota. Therefore, probiotics can work as a 
supplement to keep the microbiota stable. 
 
What can be said about the META-analysis studied is that most of the probiotics 
used showed a significant effect when treating diseases. There is evidence that pro-
biotics show effect although it can be a little effect. As probiotic bacteria are divided 
not only in species but also in strains there are a wide range of probiotics available. 
To get the best effect out of a probiotic supplement one must keep in mind that 
different strains contribute with different effects when treating a disease. Also, the 
duration of treat, the dose and a continuous intake plays a big part in the outcome.  
 
One must put great importance in what probiotic that is chosen for treating a specific 
disease. 
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Probiotics have been well established since the beginning of the 20th century but it 
is not until the last decade it has been a hot topic due to the trends of being healthy. 
The aim of this study was to get a greater knowledge about the most common pro-
biotic strains used in Sweden and to get an understanding in how the mechanism of 
action works. Even if there are much more to discover there is evidence that probi-
otics contribute to a better health. Most of all clinical studies and META-analysis 
read in this report showed that probiotics was favorable when treating different dis-
eases. When choosing a probiotic one should pay attention to which disease to be 
treated. There are still lots to discover and much more to research, but the future is 
bright, and probiotics is on the move. 
 
6 Summary 
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